Trial
NCT03071692
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Kowa Research Institute, Inc.
Collaborators
Brigham and Women's Hospital
Condition
Type2 Diabetes
Intervention
K-877
Why stopped
The study was stopped for futility based on efficacy results at the interim analysis; no unexpected safety findings were observed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-25